NCT05618626 Prevention of NAFLD and CVD Through Lifestyle Intervention
| NCT ID | NCT05618626 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Condition | Non-Alcoholic Fatty Liver Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-09-27 |
| Primary Completion | 2025-04-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2021-09-27 with a primary completion date of 2025-04-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.
Eligibility Criteria
Inclusion Criteria: * With and without gallstones disease * With various degrees of NAFLD (none too severe) Exclusion Criteria: * Any significant comorbidity or physical limitation to undergo resistance exercise program * Use of medications that alter muscle mass (e.g., corticosteroids) * History of hepatitis B or C * Use of hepatotoxic drugs
Contact & Investigator
Catterina Ferreccio, MD
PRINCIPAL INVESTIGATOR
Pontificia Universidad Catolica de Chile
Frequently Asked Questions
Who can join the NCT05618626 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 60 Years, studying Non-Alcoholic Fatty Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05618626 currently recruiting?
Yes, NCT05618626 is actively recruiting participants. Contact the research team at leahuidobro@gmail.com for enrollment information.
Where is the NCT05618626 trial being conducted?
This trial is being conducted at Molina, Chile.
Who is sponsoring the NCT05618626 clinical trial?
NCT05618626 is sponsored by Pontificia Universidad Catolica de Chile. The principal investigator is Catterina Ferreccio, MD at Pontificia Universidad Catolica de Chile. The trial plans to enroll 300 participants.